生命科学资讯

Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates

Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout

GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'

Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks

FDA demands better response from Abbott over Libre inspection violations

Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq

Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform

NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable

Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1

Amgen advances toward lupus redemption while gastric cancer candidate struggles

HHS launches $100M antiviral prize to develop broad-spectrum therapies

NIH turmoil takes center stage as director acknowledges no vaccine-autism link

Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges

Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed

FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases

Charles River to close cell therapy CDMO site, lay off 20 staffers

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b

NMD flunks rare disease trial but flexes secondary data to accelerate program

Quest launches residual disease blood test for multiple myeloma

How Mirum is Advancing Rare Disease Care Through Strategic M&A